08.16.16
Crown Bioscience has expanded its oncology services with new models, cell lines and assays at its Center of Excellence for Oncology in San Diego.
The new services include a range of platforms for the evaluation of immuno-oncology programs, and add new technologies for traditional oncology agents. CrownBio has added a portfolio of highly characterized syngeneic in vivo services, and expanded its flow cytometry labs to support both syngeneic and humanized PDX studies.
Mike Prosser, CrownBio’s general manager of European and North American operations, said, “Following the recent investment in our U.S. site, we now have the capability to offer a significantly extended range of services, from in vitro screening to later stage translational studies, including avatar clinical trials (HuTrials™) with Humanized NSG™ xenografts to evaluate the efficacy of anticancer immunotherapy before entering the clinic.”
CrownBio has also developed new PDX derived cell lines to enhance its PrimePanel collection and has developed expanded 3D-tumor growth assays (3D-TGA) for most indications to provide translational in vitro models aligned to the tumor microenvironment.
“These new services will allow us to provide our clients, leading global biopharmaceutical companies, with local access to a range of platforms, including advanced models that more accurately reflect tumor microenvironments, thereby offering better screening tools for evaluating innovative oncology drug candidates,” said Jean-Pierre Wery, Ph.D., chief executive officer of CrownBio.
The new services include a range of platforms for the evaluation of immuno-oncology programs, and add new technologies for traditional oncology agents. CrownBio has added a portfolio of highly characterized syngeneic in vivo services, and expanded its flow cytometry labs to support both syngeneic and humanized PDX studies.
Mike Prosser, CrownBio’s general manager of European and North American operations, said, “Following the recent investment in our U.S. site, we now have the capability to offer a significantly extended range of services, from in vitro screening to later stage translational studies, including avatar clinical trials (HuTrials™) with Humanized NSG™ xenografts to evaluate the efficacy of anticancer immunotherapy before entering the clinic.”
CrownBio has also developed new PDX derived cell lines to enhance its PrimePanel collection and has developed expanded 3D-tumor growth assays (3D-TGA) for most indications to provide translational in vitro models aligned to the tumor microenvironment.
“These new services will allow us to provide our clients, leading global biopharmaceutical companies, with local access to a range of platforms, including advanced models that more accurately reflect tumor microenvironments, thereby offering better screening tools for evaluating innovative oncology drug candidates,” said Jean-Pierre Wery, Ph.D., chief executive officer of CrownBio.
